2-三甲基甲硅烷基噁唑 | 120629-79-0

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 中文名称: 2-三甲基甲硅烷基噁唑
• 英文名称: 2-(Trimethylsilyl)-1,3-oxazole
• 英文别名: 2-(trimethylsilyl)oxazole；2-trimethylsilyl oxazole；trimethyl(1,3-oxazol-2-yl)silane
• CAS: 120629-79-0
• 化学式: C₆H₁₁NOSi
• mdl: MFCD17169831
• 分子量: 141.245
• InChiKey: QBGHXHYNISNLDP-UHFFFAOYSA-N

物化性质

• 沸点：
  136.9±23.0 °C(Predicted)
• 密度：
  0.94±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl {(5S)-5-[(tert-butoxycarbonyl)amino]-6-oxohexyl}carbamate 、 2-三甲基甲硅烷基噁唑 在 四丁基氟化铵 作用下， 以 甲苯 、 四氢呋喃 为溶剂， 反应 62.0h， 以18%的产率得到Boc-Lys(Cbz)ψ[CHOH]-(2-oxazolyl)
  参考文献：
  名称：

  Unique Overlap in the Prerequisites for Thrombin Inhibition and Oral Bioavailability Resulting in Potent Oral Antithrombotics

  摘要：

  Despite intense research over the last 10 years, aided by the availability of X-ray structures of enzyme-inhibitor complexes, only very few truly orally active thrombin inhibitors have been found. We conducted a comprehensive study starting with peptide transition state analogues (TSA). Both hydrophobic nonpeptide analogues as well as hydrophilic peptidic analogues were synthesized. The bioavailability in rats and dogs could be drastically altered depending on the overall charge distribution in the molecule. Compound 27, a tripeptide TSA inhibitor of thrombin, showed an oral bioavailability of 32% in rats and 71% in dogs, elimination half-lives being 58 and 108 min, respectively. The thrombin inhibition constant of compound 27 was 1.1 nM, and in an in vivo arterial flow model, the ED50 was 5.4 nmol/kg(.)min, comparable to known non-TSA inhibitors. A molecular design was found that combines antithrombotic efficiency with oral bioavailability at low dosages.

  DOI：

  10.1021/jm011110z
• 作为产物：
  描述：

  ((Z)-2-Isocyano-vinyloxy)-trimethyl-silane 在 氢氧化钾 作用下， 生成 2-三甲基甲硅烷基噁唑
  参考文献：
  名称：

  Reactions of lithiooxazole

  摘要：

  DOI：

  10.1021/jo00001a087

文献信息

• Heterocyclic ketones
  申请人：ICI Americas Inc.

  公开号：US05164371A1

  公开（公告）日：1992-11-17

  The invention provides a series of novel heterocyclic ketones of formula I ##STR1## and pharmaceutically acceptable base-addition salts thereof, in which the values of R.sup.4, L, A, X and Q have the meanings defined in the following specification. The compounds of formula I are inhibitors of human leukocytic elastase. The invention also provides pharmaceutical compositions containing a compound of formula I, or a pharmaceutically acceptable base-addition salt thereof, and processes and intermediates for the manufacture of compounds of formula I.

  这项发明提供了一系列新颖的杂环酮化合物，其化学式为I ##STR1## 及其药用可接受的盐，其中R.sup.4、L、A、X和Q的值如下文规定。化合物I的是人类白细胞弹性蛋白酶的抑制剂。该发明还提供了含有化合物I或其药用可接受的盐的药物组合物，以及化合物I的制备过程和中间体。
• HODGES, JOHN C.;PATT, WILLIAM C.;CONNOLLY, CLEO J., J. ORG. CHEM., 56,(1991) N, C. 449-452
  作者：HODGES, JOHN C.、PATT, WILLIAM C.、CONNOLLY, CLEO J.

  DOI：——

  日期：——
• [EN] COMPOUNDS AS CCR2 MODULATORS<br/>[FR] COMPOSÉS UTILISÉS COMME MODULATEURS DE CCR2
  申请人：[en]ARIA PHARMACEUTICALS, INC.

  公开号：WO2023081666A1

  公开（公告）日：2023-05-11

  The present disclosure relates generally to small molecule modulators of chemotactic cytokines (chemokine) receptors CCR2, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
• Unique Overlap in the Prerequisites for Thrombin Inhibition and Oral Bioavailability Resulting in Potent Oral Antithrombotics
  作者：Anton E. P. Adang、Adrianus P. A. de Man、Gerard M. T. Vogel、Peter D. J. Grootenhuis、Martin J. Smit、Co A. M. Peters、Arie Visser、Jos B. M. Rewinkel、Theo van Dinther、Hans Lucas、Jan Kelder、Sjoerd van Aelst、Dick G. Meuleman、Constant A. A. van Boeckel

  DOI：10.1021/jm011110z

  日期：2002.9.1

  Despite intense research over the last 10 years, aided by the availability of X-ray structures of enzyme-inhibitor complexes, only very few truly orally active thrombin inhibitors have been found. We conducted a comprehensive study starting with peptide transition state analogues (TSA). Both hydrophobic nonpeptide analogues as well as hydrophilic peptidic analogues were synthesized. The bioavailability in rats and dogs could be drastically altered depending on the overall charge distribution in the molecule. Compound 27, a tripeptide TSA inhibitor of thrombin, showed an oral bioavailability of 32% in rats and 71% in dogs, elimination half-lives being 58 and 108 min, respectively. The thrombin inhibition constant of compound 27 was 1.1 nM, and in an in vivo arterial flow model, the ED50 was 5.4 nmol/kg(.)min, comparable to known non-TSA inhibitors. A molecular design was found that combines antithrombotic efficiency with oral bioavailability at low dosages.
• Reactions of lithiooxazole
  作者：John C. Hodges、William C. Patt、Cleo J. Connolly

  DOI：10.1021/jo00001a087

  日期：1991.1